Discover how Syntegon delivered 8 high-potent ADC vial filling lines in China, supporting fast, high-quality pharma production.
Key takeaways
- Syntegon was commissioned for 8 high-potent ADC vial filling lines for Chinese customers in 2025, contributing to a record year of the pharma business.
- ADCs are rapidly expanding beyond oncology, with rising development activity and increasing demand for precise, high-quality vial filling.
- Success is driven by fast delivery, strong local presence, and integrated line solutions that improve yield, regulatory compliance, and operator protection.
Antibody drug conjugates (ADCs) are on the rise. According to a recent report from GlobalData, these innovative biopharmaceutical products are currently transitioning from a niche area to a major commercial modality. In fact, an increasing number of ADCs are set to reach blockbuster status, while the total number of ADCs that are actively being developed or marketed has tripled over the last five years. While most ADCs developed so far are treating cancer, there is also enormous potential in other areas such as autoimmune and infectious diseases as well as cardiovascular and metabolic disorders.
ADCs are almost exclusively produced as lyophilized solutions. Since these high-potent drugs are very cost-intensive, it is essential that every single vial is adequately filled and delivered to patients in the highest possible quality. Aside from product yield, thorough protection of products and operators in line with international regulations is one of the most important prerequisites. This is where Syntegon’s seamless approach comes into play: We deliver all equipment from a single source and reduce process risks as well as human intervention through integrated line design.
A highly successful year for Syntegon in China
China is the leading market for early-stage ADC development and trial initiation, with above-average patent filings, and a growing installed base of production lines. It makes us especially proud that we are among the preferred suppliers for many pharmaceutical manufacturers and CDMOs in this important market. The success of 2025 delivers the perfect proof that we have the right strategy in place for long-term co-creation and collaboration. So what clinched the decision for our customers?
Success factors at a glance
- Unrivalled delivery time of only 14 months
- The highest quality made in China
- Long-standing expertise and trustful relationships
- Exemplary line to demonstrate capabilities on-site
- Immediate availability of important options
- Local after-market services and upgrade options
It is a combination of many different factors – from customer proximity in China and fast delivery times at a competitive price to high-end quality including long-standing barrier systems expertise through to essential add-on options and local after-market services. Among the add-on options, two are especially sought-after: the offline and stand-alone online glove testing systems and our intelligent MaxPro features, which are designed to prevent human error, minimize product loss, and enhance product yield. But most importantly, it is our commitment to true co-creation and co-success with our customers.
Our portfolio for ADC lines at a glance
- RRU cleaning machines
- HQL sterilization tunnels
- ALF vial filling machines
- Toxic isolators
- Lyomega freeze-dryers
- VRK crimping machines
- RAN external cleaning machine
- Various further options, e.g. automated filter test racks for PUPSIT and Settle Plate Changer
- After-sales services & upgrades
Let’s co-create your ideal ADC line!
Our partners in China and around the world rely on Syntegon as their strategic lifecycle partner for future-proof ADC lines. Our seamless vial portfolio supports you in bringing your ADC products to market quickly, in the highest quality, and with the right output. We look forward to discussing your ADC vial project!
Syntegon Newsletter
Get inspired with regular updates on technologies and services, case studies, webinar offers and events.